Inhibikase Therapeutics, Inc.— Sankey Diagram
Annual mode · period ending 2025-12-31 · SEC EDGAR
FY2025 - Q4(Oct 25 · Nov 25 · Dec 25)
Total Assets
$181M
↑+83.8% +$83Mvs FY2024
Total Liabilities
$8M
↑+122.3% +$5Mvs FY2024
Equity
$173M
↑+82.3% +$78Mvs FY2024
Cash
$179M
↑+83.4% +$81Mvs FY2024
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 | FY2024 |
|---|---|---|
| Total Assets | $181M | $99M |
| Current Assets | $180M | $98M |
| Cash | $179M | $98M |
| ST Investments | $40M | $41M |
| Receivables | $0 | $0 |
| Inventory | $0 | $0 |
| Other Current | $0 | $0 |
| Non-Current Assets | $1M | $149K |
| PPE | $0 | $47K |
| Goodwill | $0 | $0 |
| Intangibles | $0 | $0 |
| Investments | $0 | $0 |
| Other Non-Current | $1M | $101K |
| Total Liab+Eq | $181M | $99M |
| Current Liab. | $8M | $4M |
| Accounts Payable | $1M | $943K |
| Short-Term Debt | $0 | $0 |
| Deferred Revenue | $0 | $0 |
| Other CL | $7M | $3M |
| Non-Current Liab. | $0 | $0 |
| Long-Term Debt | $0 | $0 |
| Other LT Liab. | $0 | $0 |
| Equity | $173M | $95M |
| Retained Earnings | $143M | $94M |
| Other Equity | $30M | $446K |
QuarterCharts · SEC EDGAR data · IKT · Comparing FY2025 vs FY2024